Herantis Pharma Plc’s financial reporting schedule and annual general meeting in 2017
Herantis Pharma Plc.
Company release 20 December 2016 at 9:00 am
Herantis Pharma Plc (“Herantis”) will publish its Financial Statements in regard to 2016 on the 28th of February 2017. The financial reporting schedule of Herantis in 2017 is as follows:
- Financial Statements bulletin in regard to 2016 on Tuesday the 28th of February 2017
- Interim Report on January-June 2017 on Tuesday the 29th of August 2017
The Annual General Meeting is planned to be held on Tuesday the 11th of April 2017. The Board of Directors will present a formal notice at a later stage.
Annual Report for 2016 will be published during the week 11/2017 in electronic format on the company’s web site.
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine for breakthroughs in unmet clinical needs. Our first-in-class assets are based on globally leading scientific research in their fields: CDNF for disease modification in neurodegenerative diseases, primarily Parkinson’s and ALS; and Lymfactin® for breast cancer associated lymphedema, with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.